YKL-40在脑胶质母细胞瘤微环境中的作用

胶质母细胞瘤是大脑及其他中枢神经系统最常见的恶性肿瘤,其复杂的肿瘤微环境是胶质母细胞瘤临床治疗的主要挑战,也是胶质母细胞瘤患者复发率高、生存率低的主要原因。YKL-40,这一分泌性蛋白质与多种类型的癌症预后不良相关,且在高级别胶质瘤尤其是胶质母细胞瘤患者中血清水平与肿瘤组织表达水平显著升高,而在低级别胶质瘤中并未发现这一特征。这提示,YKL-40与胶质瘤分级及胶质母细胞瘤恶性发展过程密切相关。针对YKL-40的抗体治疗也被证明能够与电离辐射协同抑制胶质母细胞瘤血管生成及恶性发展。基于YKL-40的临床价值,本文将从肿瘤微环境的角度,归纳总结YKL-40在恶性肿瘤中的相关研究成果,并讨论其在胶质母细胞瘤发生发展中的相关作用及临床应用前景。

Role of YKL-40 in the Microenvironment of Glioblastoma

Glioblastoma (GBM) is the most common malignant tumor of the brain and central nervous system. The complex tumor microenvironment of glioblastoma is considered as the main challenge for clinical treatment of glioblastoma, also the main reason for the high recurrence rate and low survival rate of glioblastoma patients. YKL-40, a secreted protein, is associated with poor prognosis in many types of solid tumors. The expression of YKL-40 in serum and tumor tissues is significantly increased in high-grade gliomas, especially in glioblastoma patients. While this feature is not found in low-grade gliomas, indicating that the expression of YKL-40 is closely related to glioma grade and malignant development. Targeted therapy using YKL-40 antibody together with ionizing radiation has also been shown to synergistically inhibit tumor angiogenesis and malignant progression in glioblastoma patients. Based on the important role of YKL-40 in regulating the tumor microenvironment, this paper summarizes the research progress of YKL-40 in malignant tumors, and discusses the related role of YKL-40 in the occurrence and development of glioblastoma and its clinical application prospect.